Healthcare AI Forum Highlights Policy, Efficiency, and Global Growth Opportunities

According to a recent LinkedIn post from Protege, the company convened hundreds of healthcare AI founders, investors, and industry leaders in San Francisco to explore where innovation is emerging across the sector. The post highlights discussions ranging from healthcare policy and payment reform to consumer AI, drug discovery, and the potential for AI-enabled care models.

Speakers cited in the post emphasized that reimbursement design may determine whether AI is used to optimize health outcomes or revenue, suggesting policy direction will be a key driver of value creation. Commentary that AI is still “97% potential energy” underscores that many healthcare AI models remain under-monetized, implying substantial upside but also execution risk for companies in this space.

Operational examples referenced in the post include a reported 97% improvement in prior authorization processing when AI is combined with open, integrated data infrastructure. If broadly replicated, such efficiency gains could lower administrative costs and support higher-margin service models for payers, providers, and infrastructure vendors, potentially expanding addressable markets for firms aligned with this workflow automation trend.

The post also points to shifting dynamics in the doctor–patient relationship, with patients using large language models to arrive better informed to clinical encounters. This could accelerate demand for AI tools that support care coordination and information synthesis, which may benefit platforms capable of integrating data across specialties and offering end-to-end decision support rather than siloed point solutions.

Global perspectives mentioned in the post suggest that the Global South may leapfrog the U.S. by building AI-native healthcare systems free of legacy constraints. For investors, this frames emerging markets as a significant opportunity for scalable AI-first health infrastructure, while also signaling competitive pressure on incumbents focused solely on mature markets.

Finally, the post references discussion of ultra-low-cost, AI-powered primary care at roughly $1 per person per month and cites research where AI diagnostic accuracy outperformed physicians in a specific study. If models delivering comparable performance can be deployed at scale, the economics of primary care and diagnostic services could be structurally transformed, creating new business models but also potential margin compression for traditional providers and technology vendors unable to adapt.

Taken together, the post suggests Protege is positioning itself at a perceived inflection point in healthcare AI, with attention on policy, infrastructure, and global deployment models rather than purely on model development. For investors, the themes described emphasize that value may accrue to firms that can convert AI’s “potential energy” into measurable clinical and financial outcomes, particularly where payment systems, integrated data, and scalable delivery models align.